Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Repligen Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WALTHAM, MASS., FEB. 24, 2026 (GLOBE NEWSWIRE) -- REPLIGEN CORPORATION (NASDAQ:RGEN), A LIFE SCIENCES COMPANY FOCUSED ON BIOPROCESSING TECHNOLOGY LEADERSHIP, TODAY REPORTED FINANCIAL RESULTS FOR ITS FOURTH QUARTER OF 2025, COVERING THE THREE- AND TWELVE- MONTH PERIODS ENDED DECEMBER 31, 2025. THE COMPANY IS ALSO PROVIDING FINANCIAL GUIDANCE FOR THE FULL YEAR 2026.

REPLIGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES 2026 FINANCIAL GUIDANCE

WEBCAST AND CONFERENCE CALL TO BE HELD TUESDAY, FEBRUARY 24, 2026, AT 8:30 A.M. ET WEBCAST AND CONFERENCE CALL TO BE HELD TUESDAY, FEBRUARY 24, 2026, AT 8:30 A.M. ET

REPLIGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

WALTHAM, MASS., JAN. 06, 2026 (GLOBE NEWSWIRE) -- REPLIGEN CORPORATION (NASDAQ:RGEN), A LIFE SCIENCES COMPANY FOCUSED ON BIOPROCESSING TECHNOLOGY LEADERSHIP, TODAY ANNOUNCED THAT THE BOARD HAS ELECTED DR. MARTIN D. MADAUS AS CHAIR OF THE BOARD, EFFECTIVE MARCH 13, 2026. AS PREVIOUSLY COMMUNICATED1, TONY HUNT IS RETIRING FROM HIS ROLE AS EXECUTIVE CHAIR AND MEMBER OF THE BOARD OF DIRECTORS EFFECTIVE THIS MARCH 13TH. MR. HUNT WILL CONTINUE TO SERVE AS AN ADVISOR TO REPLIGEN THROUGH MARCH 2027.

REPLIGEN EXECUTIVE CHAIR TONY HUNT TO RETIRE; DR. MARTIN D. MADAUS ELECTED CHAIR

WALTHAM, MASS., DEC. 18, 2025 (GLOBE NEWSWIRE) -- REPLIGEN CORPORATION (NASDAQ:RGEN), A LIFE SCIENCES COMPANY FOCUSED ON BIOPROCESSING TECHNOLOGY LEADERSHIP, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE J.P. MORGAN 2026 HEALTHCARE CONFERENCE, BEING HELD JANUARY 12  15 IN SAN FRANCISCO. OLIVIER LOEILLOT, PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PRESENT AN OVERVIEW OF THE COMPANY ON TUESDAY, JANUARY 13 AT 2:15 P.M. PT.

REPLIGEN CORPORATION TO PRESENT AT J.P. MORGAN 2026 HEALTHCARE CONFERENCE

WALTHAM, MASS., DEC. 16, 2025 (GLOBE NEWSWIRE) -- REPLIGEN CORPORATION (NASDAQ:RGEN), A LIFE SCIENCES COMPANY FOCUSED ON BIOPROCESSING TECHNOLOGY LEADERSHIP, TODAY ANNOUNCED THE LAUNCH OFTHREE NEW HIGH-PERFORMANCE CHROMATOGRAPHY RESINS: AVIPURE HIPER AAV9 AND AVIPURE HIPER AAV8 AFFINITY RESINS, ALONG WITH HIPER QA ANION EXCHANGE RESIN, EXPANDING THE COMPANY'S GROWING PROTEINS PORTFOLIO AND REINFORCING ITS COMMITMENT TO INNOVATION IN NEXT-GENERATION BIOPROCESSING. BUILT ON THE TANTTI DULOCORE BASE BEAD TECHNOLOGY, THE NEW CONVECTIVE HIPER RESINS DELIVER THE DIFFERENTIATED PERFORMANCE REQUIRED FOR NEW MODALITIES, INCLUDING VIRAL VECTORS. THESE SOLUTIONS ARE ENGINEERED TO HELP GENE THERAPY DEVELOPERS ACCELERATE PRODUCT DEVELOPMENT, IMPROVE MOLECULE STABILITY, AND ENHANCE PROCESS ECONOMICS, ULTIMATELY ENABLING FASTER, MORE RELIABLE PATHS TO MARKET. AS MOMENTUM CONTINUES ACROSS NEW MODALITIES, REPLIGEN REMAINS FOCUSED ON PROVIDING CUSTOMERS WITH THE CUTTING-EDGE TOOLS THEY NEED. THESE NEW RESINS EXTEND THE COMPANY'S LEADERSHIP IN PROCESS PRODUCTIVITY AND STRENGTHEN ITS PORTFOLIO AHEAD OF BROADER CHROMATOGRAPHY RESIN LAUNCHES ANTICIPATED IN 2026. THESE NEW RESINS FURTHER EXPAND OUR GROWING PROTEINS PORTFOLIO WITH PURPOSE-BUILT, NEXT-GENERATION TOOLS THAT LEVERAGE BOTH OUR AVIPURE AFFINITY LIGANDS AND HIPER BEAD TECHNOLOGIES, SAID UMAY SAPLAKOLU, VICE PRESIDENT, PROTEINS AND INCUBATOR AT REPLIGEN. GENE THERAPY MANUFACTURERS NEED SCALABLE, HIGH-PERFORMANCE SOLUTIONS. OUR LATEST AAV8 AND AAV9 RESINS, ALONG WITH OUR HIPER QA ANION-EXCHANGE RESIN, ARE DESIGNED TO DELIVER SIGNIFICANTLY FASTER PROCESSING AND ROBUST PERFORMANCE ACROSS TODAY'S INCREASINGLY COMPLEX BIOTHERAPEUTIC WORKFLOWS. ABOUT REPLIGEN CORPORATION REPLIGEN CORPORATION IS A GLOBAL LIFE SCIENCES COMPANY THAT DEVELOPS AND COMMERCIALIZES HIGHLY INNOVATIVE BIOPROCESSING TECHNOLOGIES AND SYSTEMS THAT ENABLE EFFICIENCIES IN THE PROCESS OF MANUFACTURING BIOLOGICAL DRUGS. WE ARE INSPIRING ADVANCES IN BIOPROCESSING FOR TH

REPLIGEN INTRODUCES NEXT-GENERATION CHROMATOGRAPHY RESINS TO ADVANCE NEW MODALITY WORKFLOWS

WALTHAM, MASS., NOV. 26, 2025 (GLOBE NEWSWIRE) -- REPLIGEN CORPORATION (NASDAQ:RGEN), A LIFE SCIENCES COMPANY FOCUSED ON BIOPROCESSING TECHNOLOGY LEADERSHIP, TODAY ANNOUNCED THAT IT WILL BE PARTICIPATE IN THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE, BEING HELD DECEMBER 2 -4 IN CORAL GABLES, FLORIDA. JASON GARLAND, CHIEF FINANCIAL OFFICER, WILL PARTICIPATE IN AN ANALYST-LED DISCUSSION ON DECEMBER 3RD AT 1:20 P.M. ET.

REPLIGEN CORPORATION TO PRESENT AT EVERCORE HEALTHCARE CONFERENCE

WALTHAM, MASS., OCT. 28, 2025 (GLOBE NEWSWIRE) -- REPLIGEN CORPORATION (NASDAQ:RGEN), A LIFE SCIENCES COMPANY FOCUSED ON BIOPROCESSING TECHNOLOGY LEADERSHIP, TODAY REPORTED FINANCIAL RESULTS FOR ITS THIRD QUARTER OF 2025, COVERING THE THREE- AND NINE- MONTH PERIODS ENDED SEPTEMBER 30, 2025. PROVIDED IN THIS PRESS RELEASE ARE FINANCIAL PERFORMANCE HIGHLIGHTS, UPDATES TO OUR GUIDANCE FOR THE FULL YEAR 2025 AND ACCESS INFORMATION FOR TODAY'S WEBCAST AND CONFERENCE CALL.

REPLIGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND UPDATES FULL YEAR 2025 FINANCIAL GUIDANCE

WALTHAM, MASS. , OCT. 15, 2025 (GLOBE NEWSWIRE) -- REPLIGEN CORPORATION (NASDAQ: RGEN) TODAY ANNOUNCED THAT THE COMPANY WILL REPORT ITS THIRD QUARTER 2025 FINANCIAL RESULTS ON TUESDAY, OCTOBER 28, 2025. THE COMPANY WILL ISSUE A PRESS RELEASE BEFORE THE MARKET OPENS AND WILL HOST A CONFERENCE CALL AT 8:30 A.

REPLIGEN TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS

WALTHAM, MASS., AUG. 22, 2025 (GLOBE NEWSWIRE) -- REPLIGEN CORPORATION (NASDAQ:RGEN), A LIFE SCIENCES COMPANY FOCUSED ON BIOPROCESSING TECHNOLOGY LEADERSHIP, TODAY ANNOUNCED THAT IT WILL BE ATTENDING THREE UPCOMING INVESTOR CONFERENCES.

REPLIGEN CORPORATION TO PRESENT AT UPCOMING SEPTEMBER CONFERENCES

WALTHAM, MASS., JULY 31, 2025 (GLOBE NEWSWIRE) -- REPLIGEN CORPORATION (NASDAQ:RGEN), A LIFE SCIENCES COMPANY FOCUSED ON BIOPROCESSING TECHNOLOGY LEADERSHIP, TODAY ANNOUNCED NOVASIGN AND REPLIGEN HAVE ENTERED INTO A STRATEGIC PARTNERSHIP TO DEVELOP AND INTEGRATE NOVASIGN'S MACHINE LEARNING AND MODELING WORKFLOW INTO REPLIGEN FILTRATION SYSTEMS. AS PART OF THE PARTNERSHIP, REPLIGEN WILL INVEST IN NOVASIGN TO HELP SCALE AND EXPAND OPERATIONS.

Repligen Corporation

RGEN

Price

Financial Reports

No items found.

Press Releases

Repligen Corporation

RGEN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

RGEN